Literature DB >> 26101993

Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.

Lei Chang1, Xiaoxiao Ye, Yajing Qiu, Gang Ma, Yunbo Jin, Hui Chen, Dongze Lv, Wenxin Yu, Xi Yang, Tianyou Wang, Xiaoxi Lin.   

Abstract

BACKGROUND: The protocol for the treatment of infantile hemangioma with propranolol varies among different clinical centers.
METHODS: Six hundred seventy-nine patients who were 1 to 12 months old were recruited in this prospective study to receive propranolol treatment. The response to the propranolol therapy was classified as 4 levels. The results were primarily evaluated using color Doppler ultrasound examinations before and after propranolol treatment.
RESULTS: The response was excellent in 176 (25.9%), good in 492 (72.5%), stable in 5 (0.7%), and poor in 6 (0.9%) of the patients. The mean age at the initiation of the therapy was 3.3 months (range, 1 to 10.9 months) and the mean duration of the therapy was 7.1 months (range, 3-17 months). The mean duration of the follow-up time after the discontinuation of the therapy was 5.3 months (range, 3-17 months). Regrowth of the hemangioma was observed in 92 cases (13.5%). Seventy-nine (11.6%) of the parents complained of their child's minor discomfort during the therapy.
CONCLUSIONS: Propranolol (2 mg/kg per day) may significantly reduce the size of a hemangioma. As an outpatient therapy, propranolol was found to be safe for Chinese children and to have minor side effects.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26101993     DOI: 10.1097/SAP.0000000000000506

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  8 in total

1.  Infantile hemangioma: factors causing recurrence after propranolol treatment.

Authors:  Lei Chang; Dongze Lv; Zhang Yu; Gang Ma; Hanru Ying; Yajing Qiu; Yifei Gu; Yunbo Jin; Hui Chen; Xiaoxi Lin
Journal:  Pediatr Res       Date:  2017-10-11       Impact factor: 3.756

2.  Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck.

Authors:  Jian-Yong Dong; Jie-Xin Ning; Kai Li; Chao Liu; Xu-Xia Wang; Rong-Hui Li; Lin-Lin Yue; Ying-Ying Huang; Shao-Hua Liu
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

3.  When to stop propranolol for infantile hemangioma.

Authors:  Lei Chang; Yifei Gu; Zhang Yu; Hanru Ying; Yajing Qiu; Gang Ma; Hui Chen; Yunbo Jin; Xiaoxi Lin
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

4.  Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study.

Authors:  Muhammad Abu-Rmaileh; Hayden C Hairston; Isabella Zaniletti; Anvesh Kompelli; Kyle P Davis; James Reed Gardner; Elijah H Bolin; Gresham T Richter
Journal:  Int J Pediatr       Date:  2022-09-09

5.  The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.

Authors:  Saul Castaneda; Samuel Melendez-Lopez; Esbeydy Garcia; Hermelinda De la Cruz; Jose Sanchez-Palacio
Journal:  Adv Ther       Date:  2016-07-26       Impact factor: 3.845

6.  Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two.

Authors:  Xueqing Li; Kun Yang; Hongwen Li; Ran Huo
Journal:  Biomed Res Int       Date:  2019-11-25       Impact factor: 3.411

7.  Color Doppler Evaluation of Arterial Resistive Index in Infantile Hemangioma: A Useful Parameter to Monitor the Response to Oral Propranolol?

Authors:  George Koshy Parapatt; Teresa Oranges; Guglielmo Paolantonio; Lucilla Ravà; Simona Giancristoforo; Andrea Diociaiuti; May El Hachem; Massimo Rollo
Journal:  Front Pediatr       Date:  2021-12-07       Impact factor: 3.569

8.  Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review.

Authors:  Mediha Kardasevic; Senka Mesihovic Dinarevic
Journal:  Med Arch       Date:  2021-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.